Search

Your search keyword '"Seier, Kenneth"' showing total 334 results
Start Over Author "Seier, Kenneth"
334 results on '"Seier, Kenneth"'

2. Surgical Site Infections in Simultaneous Colorectal and Liver Resections for Metastatic Colorectal Adenocarcinoma

Author

Schleimer, Lauren E., Hakki, Lynn, Seier, Kenneth, Seo, Susan K., Cohen, Nina, Usiak, Shauna, Romero, Tiffany, Kamboj, Mini, Ilagan, Crisanta, Saadat, Lily V., Alessandris, Remo, Soares, Kevin C., Drebin, Jeffrey, Wei, Alice C., Widmar, Maria, Wei, Iris H., Smith, J. Joshua, Pappou, Emmanouil P., Paty, Philip B., Nash, Garrett M., Jarnagin, William R., Garcia-Aguilar, Julio, Gonen, Mithat, Kingham, T. Peter, Weiser, Martin R., and D’Angelica, Michael I.

Published
2025
Full Text
View/download PDF

3. ASO Visual Abstract: Surgical Site Infections in Simultaneous Colorectal and Liver Resections for Metastatic Colorectal Adenocarcinoma

Author

Schleimer, Lauren E., Hakki, Lynn, Seier, Kenneth, Seo, Susan K., Cohen, Nina, Usiak, Shauna, Romero, Tiffany, Kamboj, Mini, Ilagan, Crisanta, Saadat, Lily V., Alessandris, Remo, Soares, Kevin C., Drebin, Jeffrey, Wei, Alice C., Widmar, Maria, Wei, Iris H., Joshua Smith, J., Pappou, Emmanouil P., Paty, Philip B., Nash, Garrett M., Jarnagin, William R., Garcia-Aguilar, Julio, Gonen, Mithat, Kingham, T. Peter, Weiser, Martin R., and D’Angelica, Michael I.

Published
2024
Full Text
View/download PDF

7. Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer

Author

McIntyre, Caitlin A., Grimont, Adrien, Park, Jiwoon, Meng, Yinuo, Sisso, Whitney J., Seier, Kenneth, Jang, Gun Ho, Walch, Henry, Aveson, Victoria G., Falvo, David J., Fall, William B., Chan, Christopher W., Wenger, Andrew, Ecker, Brett L., Pulvirenti, Alessandra, Gelfer, Rebecca, Zafra, Maria Paz, Schultz, Nikolaus, Park, Wungki, O’Reilly, Eileen M., Houlihan, Shauna L., Alonso, Alicia, Hissong, Erika, Church, George M., Mason, Christopher E., Siolas, Despina, Notta, Faiyaz, Gonen, Mithat, Dow, Lukas E., Jarnagin, William R., and Chandwani, Rohit

Published
2024
Full Text
View/download PDF

8. Correction: Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group’s clinical trial E3999

Author

Rapaport, Franck, Seier, Kenneth, Neelamraju, Yaseswini, Hassane, Duane, Baslan, Timour, Gildea, Daniel T., Haddox, Samuel, Lee, Tak, Murdock, H. Moses, Sheridan, Caroline, Thurmond, Alexis, Wang, Ling, Carroll, Martin, Cripe, Larry D., Fernandez, Hugo, Mason, Christopher E., Paietta, Elisabeth, Roboz, Gail J., Sun, Zhuoxin, Tallman, Martin S., Zhang, Yanming, Gönen, Mithat, Levine, Ross, Melnick, Ari M., Kleppe, Maria, and Garrett-Bakelman, Francine E.

Published
2023
Full Text
View/download PDF

11. Genome-Derived Ampullary Adenocarcinoma Classifier and Postresection Prognostication.

Author

Ecker, Brett L., Seier, Kenneth, Eckhoff, Austin M., Tortorello, Gabriella N., Allen, Peter J., Balachandran, Vinod P., Blackburn, Nicola, D'Angelica, Michael I., DeMatteo, Ronald P., Blazer III, Daniel G., Drebin, Jeffrey A., Fisher, William E., Fortuna, Danielle, Gill, Anthony J., Gingras, Marie-Claude, Kingham, T. Peter, Lee IV, Major K., Lidsky, Michael E., Nussbaum, Daniel P., and Overman, Michael J.

Published
2024
Full Text
View/download PDF

13. Patient satisfaction with cancer care delivery through telemedicine at a comprehensive cancer center across three years during and after the COVID-19 pandemic.

Author

Doshi, Sahil D, primary, Khadem Charvadeh, Yasin, additional, Seier, Kenneth, additional, Bange, Erin Mary, additional, Daly, Robert Michael, additional, Polubriaginof, Fernanda C. G., additional, Buckley, Michael T., additional, Kuperman, Gilad, additional, Stetson, Peter D., additional, Schrag, Deb, additional, Morris, Michael J., additional, and Panageas, Katherine, additional

Published
2024
Full Text
View/download PDF

16. Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group’s clinical trial E3999

Author

Rapaport, Franck, Seier, Kenneth, Neelamraju, Yaseswini, Hassane, Duane, Baslan, Timour, Gildea, Daniel T., Haddox, Samuel, Lee, Tak, Murdock, H. Moses, Sheridan, Caroline, Thurmond, Alexis, Wang, Ling, Carroll, Martin, Cripe, Larry D., Fernandez, Hugo, Mason, Christopher E., Paietta, Elisabeth, Roboz, Gail J., Sun, Zhuoxin, Tallman, Martin S., Zhang, Yanming, Gönen, Mithat, Levine, Ross, Melnick, Ari M., Kleppe, Maria, and Garrett-Bakelman, Francine E.

Published
2022
Full Text
View/download PDF

19. Impact of Delirium Onset and Duration on Mortality in Patients With Cancer Admitted to the ICU.

Author

Tao, Jing, Seier, Kenneth P., Chawla, Sanjay, Tan, Kay See, Wheeler, Amanda, Sanzone, Joanna, Marasigan-Stone, Carina B., Simondac, Justina-Sheila S., Pascual, Analin V., Kostelecky, Natalie T., and Voigt, Louis P.

Subjects
*DELIRIUM, *INTENSIVE care units, *CANCER-related mortality, *CRITICALLY ill patient care, *LENGTH of stay in hospitals, *HOSPITAL mortality
Abstract

Background: Little is known on the effects of delirium onset and duration on outcome in critically ill patients with cancer. Objectives: To determine the impact of delirium onset and duration on intensive care unit (ICU) and hospital mortality and length of stay (LOS) in patients with cancer. Methods: Of the 915 ICU patients admitted in 2018, 371 were included for analysis after excluding for terminal disease, <24-h ICU stay, lack of active cancer and delirium. Delirium was defined as early if onset was within 2 days of ICU admission, late if onset was on day 3 or later, short if duration was 2 days or less, and long if duration was 3 days or longer. Patients were placed into 4 combination groups: early-short, early-long, late-short, and late-long delirium. Multivariate analysis controlling for sex, age, metastatic disease, and predelirium hospital LOS was performed to determine ICU and hospital mortality and LOS. Exploratory analysis of long-term survival was also performed. Restricted cubic splines were performed to confirm the use of 2 days to distinguish between early versus late onset and short versus long duration. Results: A total of 32.9% (n = 122) patients had early-short, 39.1% (n = 145) early-long, 16.2% (n = 60) late-short, and 11.9% (n = 44) late-long delirium. Late-long delirium was independently associated with increased ICU (OR 4.45, CI 1.92-10.30; P <.001) and hospital (OR 2.91, CI 1.37-6.19; P =.005) mortality and longer ICU (OR 1.97, CI 1.58-2.47; P <.001) LOS compared to early-short delirium. Early delirium had better overall survival at 18 months than late delirium. Long-term survival further improved when delirium duration was 2 days or less. Prediction heatmaps confirm the use of a 2-day cutoff. Conclusion: Late delirium, especially with long duration, significantly worsens outcome in ICU patients with cancer and should be considered a harbinger of poor overall condition. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Supplementary Table S3 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma

Author

Gleason, Caroline E., primary, Dickson, Mark A., primary, Klein (Dooley), Mary E., primary, Antonescu, Cristina R., primary, Gularte-Mérida, Rodrigo, primary, Benitez, Marimar, primary, Delgado, Juliana I., primary, Kataru, Raghu P., primary, Tan, Mark Wei Yi, primary, Bradic, Martina, primary, Adamson, Travis E., primary, Seier, Kenneth, primary, Richards, Allison L., primary, Palafox, Marta, primary, Chan, Eric, primary, D'Angelo, Sandra P., primary, Gounder, Mrinal M., primary, Keohan, Mary Louise, primary, Kelly, Ciara M., primary, Chi, Ping, primary, Movva, Sujana, primary, Landa, Jonathan, primary, Crago, Aimee M., primary, Donoghue, Mark T.A., primary, Qin, Li-Xuan, primary, Serra, Violetta, primary, Turkekul, Mesruh, primary, Barlas, Afsar, primary, Firester, Daniel M., primary, Manova-Todorova, Katia, primary, Mehrara, Babak J., primary, Kovatcheva, Marta, primary, Tan, Nguan Soon, primary, Singer, Samuel, primary, Tap, William D., primary, and Koff, Andrew, primary

Published
2024
Full Text
View/download PDF

23. Supplementary Figure S15 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma

Author

Gleason, Caroline E., primary, Dickson, Mark A., primary, Klein (Dooley), Mary E., primary, Antonescu, Cristina R., primary, Gularte-Mérida, Rodrigo, primary, Benitez, Marimar, primary, Delgado, Juliana I., primary, Kataru, Raghu P., primary, Tan, Mark Wei Yi, primary, Bradic, Martina, primary, Adamson, Travis E., primary, Seier, Kenneth, primary, Richards, Allison L., primary, Palafox, Marta, primary, Chan, Eric, primary, D'Angelo, Sandra P., primary, Gounder, Mrinal M., primary, Keohan, Mary Louise, primary, Kelly, Ciara M., primary, Chi, Ping, primary, Movva, Sujana, primary, Landa, Jonathan, primary, Crago, Aimee M., primary, Donoghue, Mark T.A., primary, Qin, Li-Xuan, primary, Serra, Violetta, primary, Turkekul, Mesruh, primary, Barlas, Afsar, primary, Firester, Daniel M., primary, Manova-Todorova, Katia, primary, Mehrara, Babak J., primary, Kovatcheva, Marta, primary, Tan, Nguan Soon, primary, Singer, Samuel, primary, Tap, William D., primary, and Koff, Andrew, primary

Published
2024
Full Text
View/download PDF

24. Data from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma

Author

Gleason, Caroline E., primary, Dickson, Mark A., primary, Klein (Dooley), Mary E., primary, Antonescu, Cristina R., primary, Gularte-Mérida, Rodrigo, primary, Benitez, Marimar, primary, Delgado, Juliana I., primary, Kataru, Raghu P., primary, Tan, Mark Wei Yi, primary, Bradic, Martina, primary, Adamson, Travis E., primary, Seier, Kenneth, primary, Richards, Allison L., primary, Palafox, Marta, primary, Chan, Eric, primary, D'Angelo, Sandra P., primary, Gounder, Mrinal M., primary, Keohan, Mary Louise, primary, Kelly, Ciara M., primary, Chi, Ping, primary, Movva, Sujana, primary, Landa, Jonathan, primary, Crago, Aimee M., primary, Donoghue, Mark T.A., primary, Qin, Li-Xuan, primary, Serra, Violetta, primary, Turkekul, Mesruh, primary, Barlas, Afsar, primary, Firester, Daniel M., primary, Manova-Todorova, Katia, primary, Mehrara, Babak J., primary, Kovatcheva, Marta, primary, Tan, Nguan Soon, primary, Singer, Samuel, primary, Tap, William D., primary, and Koff, Andrew, primary

Published
2024
Full Text
View/download PDF

25. Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma

Author

Teo, Min Yuen, Al-Ahmadie, Hikmat, Seier, Kenneth, Tully, Christopher, Regazzi, Ashley M., Pietzak, Eugene, Solit, David B., Tickoo, Satish, Reuter, Victor, Cha, Eugene K., Herr, Harry, Donahue, Timothy, Donat, Sherri M., Dalbagni, Guido, Bochner, Bernard H., Funt, Samuel, Iyer, Gopakumar V., Bajorin, Dean F., Ostrovnaya, Irina, and Rosenberg, Jonathan E.

Published
2021
Full Text
View/download PDF

29. Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement

Author

Jolissaint, Joshua S., Reyngold, Marsha, Bassmann, Jared, Seier, Kenneth P., Gönen, Mithat, Varghese, Anna M., Yu, Kenneth H., Park, Wungki, O’Reilly, Eileen M., Balachandran, Vinod P., D’Angelica, Michael I., Drebin, Jeffrey A., Kingham, T. Peter, Soares, Kevin C., Jarnagin, William R., Crane, Christopher H., and Wei, Alice C.

Published
2021
Full Text
View/download PDF

30. Correction: Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma

Author

Teo, Min Yuen, Al-Ahmadie, Hikmat, Seier, Kenneth, Tully, Christopher, Regazzi, Ashley M., Pietzak, Eugene, Solit, David B., Tickoo, Satish, Reuter, Victor, Cha, Eugene K., Herr, Harry, Donahue, Timothy, Donat, Sherri M., Dalbagni, Guido, Bochner, Bernard H., Funt, Samuel, Iyer, Gopakumar V., Bajorin, Dean F., Ostrovnaya, Irina, and Rosenberg, Jonathan E.

Published
2022
Full Text
View/download PDF

31. CT radiomics associations with genotype and stromal content in pancreatic ductal adenocarcinoma

Author

Attiyeh, Marc A., Chakraborty, Jayasree, McIntyre, Caitlin A., Kappagantula, Rajya, Chou, Yuting, Askan, Gokce, Seier, Kenneth, Gonen, Mithat, Basturk, Olca, Balachandran, Vinod P., Kingham, T. Peter, D’Angelica, Michael I., Drebin, Jeffrey A., Jarnagin, William R., Allen, Peter J., Iacobuzio-Donahue, Christine A., Simpson, Amber L., and Do, Richard K.

Published
2019
Full Text
View/download PDF

32. Supplementary Data from Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas

Author

Rosenbaum, Evan, primary, Seier, Kenneth, primary, Bradic, Martina, primary, Kelly, Ciara, primary, Movva, Sujana, primary, Nacev, Benjamin A., primary, Gounder, Mrinal M., primary, Keohan, Mary L., primary, Avutu, Viswatej, primary, Chi, Ping, primary, Thornton, Katherine A., primary, Chan, Jason E., primary, Dickson, Mark A., primary, Donoghue, Mark T.A., primary, Tap, William D., primary, Qin, Li-Xuan, primary, and D'Angelo, Sandra P., primary

Published
2023
Full Text
View/download PDF

33. TABLE 3 from Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas

Author

Rosenbaum, Evan, primary, Seier, Kenneth, primary, Bradic, Martina, primary, Kelly, Ciara, primary, Movva, Sujana, primary, Nacev, Benjamin A., primary, Gounder, Mrinal M., primary, Keohan, Mary L., primary, Avutu, Viswatej, primary, Chi, Ping, primary, Thornton, Katherine A., primary, Chan, Jason E., primary, Dickson, Mark A., primary, Donoghue, Mark T.A., primary, Tap, William D., primary, Qin, Li-Xuan, primary, and D'Angelo, Sandra P., primary

Published
2023
Full Text
View/download PDF

34. TABLE 4 from Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas

Author

Rosenbaum, Evan, primary, Seier, Kenneth, primary, Bradic, Martina, primary, Kelly, Ciara, primary, Movva, Sujana, primary, Nacev, Benjamin A., primary, Gounder, Mrinal M., primary, Keohan, Mary L., primary, Avutu, Viswatej, primary, Chi, Ping, primary, Thornton, Katherine A., primary, Chan, Jason E., primary, Dickson, Mark A., primary, Donoghue, Mark T.A., primary, Tap, William D., primary, Qin, Li-Xuan, primary, and D'Angelo, Sandra P., primary

Published
2023
Full Text
View/download PDF

35. Data from Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas

Author

Rosenbaum, Evan, primary, Seier, Kenneth, primary, Bradic, Martina, primary, Kelly, Ciara, primary, Movva, Sujana, primary, Nacev, Benjamin A., primary, Gounder, Mrinal M., primary, Keohan, Mary L., primary, Avutu, Viswatej, primary, Chi, Ping, primary, Thornton, Katherine A., primary, Chan, Jason E., primary, Dickson, Mark A., primary, Donoghue, Mark T.A., primary, Tap, William D., primary, Qin, Li-Xuan, primary, and D'Angelo, Sandra P., primary

Published
2023
Full Text
View/download PDF

36. TABLE 2 from Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas

Author

Rosenbaum, Evan, primary, Seier, Kenneth, primary, Bradic, Martina, primary, Kelly, Ciara, primary, Movva, Sujana, primary, Nacev, Benjamin A., primary, Gounder, Mrinal M., primary, Keohan, Mary L., primary, Avutu, Viswatej, primary, Chi, Ping, primary, Thornton, Katherine A., primary, Chan, Jason E., primary, Dickson, Mark A., primary, Donoghue, Mark T.A., primary, Tap, William D., primary, Qin, Li-Xuan, primary, and D'Angelo, Sandra P., primary

Published
2023
Full Text
View/download PDF

37. TABLE 1 from Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas

Author

Rosenbaum, Evan, primary, Seier, Kenneth, primary, Bradic, Martina, primary, Kelly, Ciara, primary, Movva, Sujana, primary, Nacev, Benjamin A., primary, Gounder, Mrinal M., primary, Keohan, Mary L., primary, Avutu, Viswatej, primary, Chi, Ping, primary, Thornton, Katherine A., primary, Chan, Jason E., primary, Dickson, Mark A., primary, Donoghue, Mark T.A., primary, Tap, William D., primary, Qin, Li-Xuan, primary, and D'Angelo, Sandra P., primary

Published
2023
Full Text
View/download PDF

38. Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas

Author

Rosenbaum, Evan, primary, Seier, Kenneth, additional, Bradic, Martina, additional, Kelly, Ciara, additional, Movva, Sujana, additional, Nacev, Benjamin A., additional, Gounder, Mrinal M., additional, Keohan, Mary L., additional, Avutu, Viswatej, additional, Chi, Ping, additional, Thornton, Katherine A., additional, Chan, Jason E., additional, Dickson, Mark A., additional, Donoghue, Mark T.A., additional, Tap, William D., additional, Qin, Li-Xuan, additional, and D'Angelo, Sandra P., additional

Published
2023
Full Text
View/download PDF

40. Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma

Author

Gleason, Caroline E., primary, Dickson, Mark A., additional, Klein (Dooley), Mary E., additional, Antonescu, Cristina R., additional, Gularte-Mérida, Rodrigo, additional, Benitez, Marimar, additional, Delgado, Juliana I., additional, Kataru, Raghu P., additional, Tan, Mark Wei Yi, additional, Bradic, Martina, additional, Adamson, Travis E., additional, Seier, Kenneth, additional, Richards, Allison L., additional, Palafox, Marta, additional, Chan, Eric, additional, D'Angelo, Sandra P., additional, Gounder, Mrinal M., additional, Keohan, Mary Louise, additional, Kelly, Ciara M., additional, Chi, Ping, additional, Movva, Sujana, additional, Landa, Jonathan, additional, Crago, Aimee M., additional, Donoghue, Mark T.A., additional, Qin, Li-Xuan, additional, Serra, Violetta, additional, Turkekul, Mesruh, additional, Barlas, Afsar, additional, Firester, Daniel M., additional, Manova-Todorova, Katia, additional, Mehrara, Babak J., additional, Kovatcheva, Marta, additional, Tan, Nguan Soon, additional, Singer, Samuel, additional, Tap, William D., additional, and Koff, Andrew, additional

Published
2023
Full Text
View/download PDF

44. A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with advanced sarcoma: Results of expansion cohorts.

Author

Kelly, Ciara Marie, primary, Avutu, Viswatej, additional, Chi, Ping, additional, Dickson, Mark Andrew, additional, Gounder, Mrinal M., additional, Keohan, Mary Louise, additional, Movva, Sujana, additional, Rosenbaum, Evan, additional, Cordover, Emma, additional, Ariyan, Charlotte Eielson, additional, Bartlett, Edmund, additional, Crago, Aimee Marie, additional, Singer, Samuel, additional, Antonescu, Cristina R., additional, Hwang, Sinchun, additional, Erinjeri, Joseph Patrick, additional, Seier, Kenneth, additional, Qin, Li-Xuan, additional, Tap, William D., additional, and D'Angelo, Sandra P., additional

Published
2023
Full Text
View/download PDF

47. Hepatic disease control in patients with intrahepatic cholangiocarcinoma correlates with overall survival

Author

Soares, Kevin C, Jolissaint, Joshua S, McIntyre, Sarah M, Seier, Kenneth P, Gönen, Mithat, Sigel, Carlie, Nasar, Naaz, Cercek, Andrea, Harding, James J, Kemeny, Nancy E, Connell, Louise C, Koerkamp, Bas Groot, Balachandran, Vinod P, D'Angelica, Michael I, Drebin, Jeffrey A, Kingham, T Peter, Wei, Alice C, Jarnagin, William R, Soares, Kevin C, Jolissaint, Joshua S, McIntyre, Sarah M, Seier, Kenneth P, Gönen, Mithat, Sigel, Carlie, Nasar, Naaz, Cercek, Andrea, Harding, James J, Kemeny, Nancy E, Connell, Louise C, Koerkamp, Bas Groot, Balachandran, Vinod P, D'Angelica, Michael I, Drebin, Jeffrey A, Kingham, T Peter, Wei, Alice C, and Jarnagin, William R

Abstract

Purpose: The role of locoregional therapy compared to systemic chemotherapy (SYS) for unresectable intrahepatic cholangiocarcinoma (IHC) remains controversial. The importance of hepatic disease control, either as initial or salvage therapy, is also unclear. We compared overall survival (OS) in patients treated with resection, hepatic arterial infusion pump (HAIP) chemotherapy, or SYS as it relates to hepatic recurrence or progression. We also evaluated recurrence after resection to determine the efficacy of locoregional salvage therapy. Patients and Methods: In this single-institution retrospective analysis, patients with biopsy-proven IHC treated with either curative-intent resection, HAIP (with or without SYS), or SYS alone were analyzed. Propensity score matching (PSM) was used to compare patients with liver-limited, advanced disease treated with HAIP versus SYS. The impact of locoregional salvage therapies in patients with liver-limited recurrence was analyzed in the resection cohort. Results: From 2000 to 2017, 714 patients with IHC were treated, 219 (30.7%) with resectable disease, 316 (44.3%) with locally advanced disease, and 179 (25.1%) with metastatic disease. Resected patients were less likely to recur or progress in the liver (hazard ratio [HR] 0.41, 95% CI 0.34–0.45) versus those that received HAIP or SYS (HR 0.58, 95% CI 0.50–0.65 vs. HR 0.63, 95% CI 0.57–0.69, respectively). In resected patients, 161 (64.4%) recurred, with 65 liver-only recurrences. Thirty of these patients received subsequent locoregional therapy. On multivariable analysis, locoregional therapy was associated with improved OS after isolated liver recurrence (HR 0.46, 95% CI 0.29–0.75; p = 0.002). In patients with locally advanced unresectable or multifocal liver disease (with or without distant organ metastases), PSM demonstrated improved hepatic progression-free survival in patients treated with HAIP versus SYS (HR 0.65; 95% CI 0.46–0.91; p = 0.01), which correlated with improved

Published
2023

49. Rehabilitation of pediatric retinoblastoma patients with ocular prostheses and their subsequent modifications: A 15‐year retrospective study.

Author

Legg, Lydia R., Ahmed, Zain Uddin, Solano, Armand K., Seier, Kenneth, O'Hara, Bridget F., Kapetanakos, Melani, Huryn, Joseph M., and Randazzo, Joseph D.

Subjects
CHILD patients, ENUCLEATION of the eye, PROSTHETICS, RETROSPECTIVE studies, REHABILITATION, ARTIFICIAL eyes
Abstract

Purpose: Enucleation is a common treatment modality performed for pediatric retinoblastoma patients, and the resultant defects are reconstructed using an ocular prosthesis. The prostheses are modified or replaced periodically, as the child develops due to orbital growth and patient‐error. The purpose of this report is to evaluate the replacement frequency of prostheses in the pediatric oncologic population. Methods: A retrospective review was completed by the two senior research investigators, of patients that had ocular prostheses fabricated following enucleation of their retinoblastoma from 2005 to 2019 (n = 90). Data collected from the medical records of the patient included the pathology, date of surgery, date of prosthesis delivery, and the replacement schedule of the ocular prosthesis. Results: During the 15‐year study period, 78 enucleated observations (ocular prosthesis fabricated) were included for analysis. The median age of the patients at the time of delivery of their first ocular prosthesis was calculated to be 2.6 years (range 0.3–18 years). The median time to the first modification of the prosthesis was calculated to be 6 months. The time to modification of the ocular prosthesis was further stratified by age. Conclusion: Pediatric patients require modification of their ocular prostheses throughout their growth and development period. Ocular prostheses are reliable prostheses with predictable outcomes. This data is helpful to set an expectation among the patient, parent, and provider. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

50. Hepatic disease control in patients with intrahepatic cholangiocarcinoma correlates with overall survival

Author

Soares, Kevin C., primary, Jolissaint, Joshua S., additional, McIntyre, Sarah M., additional, Seier, Kenneth P., additional, Gönen, Mithat, additional, Sigel, Carlie, additional, Nasar, Naaz, additional, Cercek, Andrea, additional, Harding, James J., additional, Kemeny, Nancy E., additional, Connell, Louise C., additional, Koerkamp, Bas Groot, additional, Balachandran, Vinod P., additional, D'Angelica, Michael I., additional, Drebin, Jeffrey A., additional, Kingham, T. Peter, additional, Wei, Alice C., additional, and Jarnagin, William R., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results